Hey refresher . I also think the price should be much higher ....

Hey refresher . I also think the price should be much higher . As you said , they have had promising results before and the price has not moved much . I think the investment community needs more concrete proof of the effectiveness of the drug . Not one clinical trial has yet been completed , amazing intrim results , but nothing completed . First quarter next year both clinicals should be finished . Then the company will sink or swim on the value of its science .
Valuetech , in their review of Solbec , say the price is about right . They dont seem to want to factor in any speculative value till they have more proof . Bios in phase 1 trials are considered high risk . Normally a phase 1 trial would do little to change that position , as it is only a safety trial . The Solbec compound has demonstrated a reaction so strong against various cancers that in this case , even the phase 1 has demonstrated efficacy in the first patients treated with tiny doses . I would be a little dubious there if I did not also know of the spectacular success on some of the special access patients .
The psoriasis trial is also due to finish 1st Q next year I think .
I dont know what sort of results will come out of Rational Therapeutics tests now being conducted in LA , but if they are anything like the last ones with the weaker form of the drug , then they should once again demonstrate a higher response rate than standard cancer drugs against the target cancers .
They are to present at the Ausbio partnering and investment forum on Nov9 . They are down as agribusiness , perhaps the vetinary application .
They are moving foreward on several fronts .Check out the current state of the company at this site .
https://www.shareanalysis.com/ASP/Company/Bluebook.asp?SecId=SBP
I would think solbec is a very good buy now to hold through next year . Just my opinion .
Cheers
Skint